ClinicalTrials.gg
Not yet recruitingNCT07395895Updated Feb 9, 2026

Effect of Metformin Iontophoresis on Knee Osteoarthritis in Postmenopausal Women

A Phase 3 interventional study of Metformin gel Iontophoresis and Iontophoresis in Osteoarthritis in Postmenopausal Women, sponsored by Badr University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Badr University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Osteoarthritis with a site in Egypt — 12 open to participants now, 12 under way, 1 of them phase 3. Osteoarthritis · Egypt.

Planned enrollment
10th of 27
68 · median 60
Started
2026
with 6 others
Phase 3
Only one
of the 33
Primary completion
2026-04
later than 5 of 11 live
Registered
27th of 33
by date
Lead sponsor
2 of 33
Badr University

Among the 33 studies in Osteoarthritis with a site in Egypt, this one is the 10th largest by planned enrollment of the 27 interventional ones that give a count, is one of 7 that started in 2026, is the only one in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 27th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

12 of the 33 studies in Osteoarthritis with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 50 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Osteoarthritis with a site in Egypt, or all of them as a file.
02

Study summary

This study is designed as a randomized, double-blind, placebo-controlled clinical trial with two parallel groups. All participants will receive a standardized physical therapy rehabilitation program. Participants will be randomly allocated into either a study group receiving metformin iontophoresis or a control group receiving placebo iontophoresis. Both participants and outcome assessors will be blinded to group allocation.

Read the detailed description

The study population will consist of postmenopausal women diagnosed with knee osteoarthritis. Postmenopause is defined as the absence of menstruation for at least 12 consecutive months. Participants will be randomly assigned to either the study or control group using a computer-generated randomization sequence. Allocation concealment will be ensured using sealed opaque envelopes. Both participants and outcome assessors will be blinded to the treatment allocation. The physical therapist applying iontophoresis will not be involved in outcome assessment.

03

Conditions studied

  • Osteoarthritis in Postmenopausal Women

Browse trials for

Keywords

  • Metformin gel
  • Iontophoresis
  • Physical Therapy Rehabilitation
  • Osteoarthritis
  • Postmenopausal Women
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • women aged 50-70 years.

      • Clinical and radiographic diagnosis of knee osteoarthritis according to the American College of Rheumatology criteria.
      • Radiographic severity classified as Kellgren-Lawrence grade II or III.
      • Chronic knee pain for a duration of at least 3 months.
      • Pain intensity ≥4 on the Visual Analog Scale.
      • Ability to ambulate independently with or without assistive devices.
      • Ability to understand and follow instructions.
      • Willingness to participate and provide written .

Exclusion criteria

Exclusion Criteria:

    • Severe knee osteoarthritis (Kellgren-Lawrence grade IV).

      • History of knee surgery or intra-articular injections within the previous 6 months.
      • Presence of inflammatory rheumatic diseases such as rheumatoid arthritis or gout.
      • Neurological disorders affecting lower limb function.
      • Uncontrolled metabolic, cardiovascular, or systemic diseases.
      • Current or recent use of metformin or other antidiabetic medications.
      • Skin lesions, infections, or at the iontophoresis site.
      • to electrotherapy such as pacemakers or implanted electronic devices.
      • ≥35 kg/m².
      • Participation in another clinical trial within the last 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
68 participants (estimated)

Study arms

  • Active comparator
    Metformin Iontophoresis

    Drug: Metformin gel Iontophoresis

  • Active comparator
    Iontophoresis Combined with Physical Therapy Rehabilitation

    Device: Iontophoresis

Interventions

  • DrugMetformin gel Iontophoresis

    Metformin gel 2% Iontophoresis Combined with Physical Therapy Rehabilitation

  • DeviceIontophoresis

    Iontophoresis with neutral gel Combined with Physical Therapy Rehabilitation

06

What researchers measure

Primary outcomes

  1. Pain intensity

    assessed using the Visual Analog Scale.

    Time frame: at baseline, after 6 weeks and after 12 weeks

  2. Functional status

    assessed using the WOMAC index

    Time frame: at baseline, after 6 weeks and after 12 weeks

07

Study locations

1 site
08

References and documents

Publications

  • 1. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage. 2019;27(11):1578-1589. 2. Kolasinski SL, Neogi T, Hochberg MC, et al. 2020 American College of Rheumatology guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care & Research. 2020;72(2):149-162. 3. Quicke JG, Foster NE, Ogollah RO, et al. Supervised exercise therapy for knee osteoarthritis: A randomized controlled trial. Ann Rheum Dis. 2022;81(3):336-343. 4. Wang Y, Hussain SM, Wluka AE, et al. Effect of exercise therapy on knee osteoarthritis: Systematic review and meta-analysis. Arthritis Res Ther. 2021;23:147. 5. Zhang W, Doherty M, Peat G, et al. EULAR evidence-based recommendations for knee osteoarthritis management. Ann Rheum Dis. 2020;79(6):685-699.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Apr 2026, 1 month later.

Of 84 phase 3 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 27. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2026
First posted
Feb 9, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Apr 15, 2026
CompletionEst.
May 1, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395895
Lead sponsor
Badr University
Responsible party
Eman Said Sawan (Lecturer, Badr University) — Principal investigator
First posted
Feb 9, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Apr 15, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Feb 9, 2026

Study contacts

‪Eman swan‬, Ph d
Contact
eman.said@buc.edu.eg
+201090111013

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion